Echolucent implant compositions and methods

Patent metadata

Field	Value
Publication number	US-11083802-B2
Application number	US-202016817291-A
Country	US
Kind code	B2
Filing date	Mar 12, 2020
Priority date	Dec 15, 2009
Publication date	Aug 10, 2021
Grant date	Aug 10, 2021

Abstract

Implantable materials visible under ultrasound may delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.

First claim

The invention claimed is:

1. A method for placement of a pharmaceutically acceptable implant into a patient comprising
delivering a pharmaceutically acceptable implant through an applicator into the patient at a selected placement site, the implant comprising a flowable, hydrolytically biodegradable polymer composition, an osmotic agent, and a therapeutic agent, wherein the flowable, hydrolytically biodegradable polymer composition comprises a collection of covalently-crosslinked hydrolytically biodegradable hydrogel particles, a hydrogel precursor composition that reacts to form covalent bonds at physiological conditions with the product being a covalently-crosslinked hydrolytically biodegradable hydrogel, or a combination thereof, wherein the implant at the selected placement site is visible under ultrasound, and wherein the therapeutic agent is released from the implant at the placement site.

2. The method of claim 1 further comprising monitoring the delivering of the implant to the placement site with ultrasound.

3. The method of claim 1 wherein the implant further comprises a pharmaceutically acceptable fluid and wherein the implant is delivered to the placement site as a slurry.

4. The method of claim 1 wherein the applicator comprises a syringe, a catheter, a needle, a double barreled container, or combinations thereof.

5. The method of claim 1 wherein the applicator comprises a syringe connected to a needle, and the delivering of the implant comprises injecting the implant through the needle into the placement site.

6. The method of claim 1 wherein the hydrogel particles have an average diameter from about 10 microns to about 500 microns.

7. The method of claim 1 wherein the hydrogel particles have an average diameter from about 125 microns to about 500 microns.

8. The method of claim 1 wherein the implant comprises an ultrasound contrast agent.

9. The method of claim 1 wherein the implant further comprises a radiopaque agent.

10. The method of claim 9 wherein the radiopaque agent is covalently attached to the polymer composition.

11. The method of claim 1 wherein the therapeutic agent comprises a pain reliever, an anesthetic, a steroid, a chemotherapeutic agent, or combinations thereof.

12. The method of claim 1 wherein the implant is adherent to a tissue at the placement site.

13. The method of claim 1 wherein a volume of the implant after delivering at the placement site is no more than 50% more than a volume of the implant prior to delivering at the placement site and wherein the porosity is more than 30%.

14. The method of claim 1 wherein the implant has a time for degradation from about 7 days to about 180 days.

15. The method of claim 1 wherein the implant is hydrolytically biodegradable to produce degradation products that are absorbed into the circulatory system and cleared from the body via renal filtration.

16. The method of claim 1 wherein the collection comprises dehydrated covalently-crosslinked hydrolytically biodegradable hydrogel particles.

17. The method of claim 1 further comprising visualizing an interface of the implant and a tissue with ultrasound, X-ray, or a combination thereof.

18. The method of claim 1 further comprising a step of mixing the polymer composition and the osmotic agent with the therapeutic agent to form the implant.

19. The method of claim 1 wherein the osmotic agent comprises polyethylene glycol.

20. The method of claim 1 wherein the therapeutic agent comprises particulates.

21. The method of claim 1 wherein the implant comprises gas microbubbles, microparticles comprising the therapeutic agent, hydrophobic microdomains, hydrogel particles, and/or microparticulates of the therapeutic agent.

22. The method of claim 1 wherein the placement site is between a first tissue location and a second tissue location.

23. The method of claim 1 wherein the placement site is a muscle tissue location and/or a nerve tissue location.

Assignees

• Incept Llc

Inventors

• Campbell Patrick
• Sawhney Amarpreet S

Classifications

• A61L27/50 Primary

  Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title

• A61L31/18

  Materials at least partially X-ray or laser opaque · CPC title

• A61L31/148

  Materials at least partially resorbable by the body · CPC title

• A61K51/1244

  microparticles or nanoparticles, e.g. polymeric nanoparticles · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title